Answers are grounded in this paper and cite their sources.
Granulocyte colony-stimulating factors, introduced in the 1990s to prevent neutropenic fever, improve patients’ prognosis after myelotoxic chemotherapy. G-CSFs accelerate bone marrow recovery, shortening the duration of neutropenia and reducing its intensity as well as the risk of febrile neutropenia. There are short- and long-acting G-CSFs available these days. This paper is a review of the efficacy, toxicity and indications for short- and long-acting G-CSFs as indicated in the most recent studies.
No takes yet. Share an insight, caveat, or question.
Sobas et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: